Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660760 · ClinicalTrials.gov registry record · Phase 2
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
A Phase 2 study of Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 and Clinical Stage IV Gastric Cancer AJCC v8, sponsored by Academic and Community Cancer Research United.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 15
- Study locations
NCT04660760 is a Phase 2 study of Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 and Clinical Stage IV Gastric Cancer AJCC v8 that is actively recruiting participants, run by Academic and Community Cancer Research United. The registered enrollment target is 116 participants, above the 92-participant average among 19 other Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 trials with a reported enrollment target (26% higher). The trial reports 15 study locations across 12 states.
The verdict
NCT04660760, a Phase 2 study of Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 and Clinical Stage IV Gastric Cancer AJCC v8, is actively recruiting participants, sponsored by Academic and Community Cancer Research United.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by targeting new blood vessel formation. Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stopping cell division which may kill tumor cells. Giving ramucirumab and trifluridine/tipiracil will not be worse than ramucirumab and paclitaxel in treating gastric or gastroesophageal junction cancer.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Paclitaxel
- BIOLOGICAL Ramucirumab
- DRUG Trifluridine and Tipiracil Hydrochloride
Study Locations (15)
Arizona
- Mayo Clinic in Arizona - Scottsdale
- Arizona Clinical Research Center - Tucson
Florida
- Mayo Clinic in Florida - Jacksonville
- Cleveland Clinic-Weston - Weston
Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay - Green Bay
- Aurora Cancer Care-Milwaukee West - Wauwatosa
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Illinois
- Carle Cancer Center NCI Community Oncology Research Program - Urbana
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04660760
The ClinicalTrials.gov registry entry for NCT04660760 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 92-participant average among 19 other Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 trials with a reported enrollment target (26% higher). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04660760 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Arizona, Florida, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04660760 about?
NCT04660760 is a clinical study titled "Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer". This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by tar...
What is the current status of trial NCT04660760?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2021-06-16. Estimated completion is 2026-05-31.
What conditions does trial NCT04660760 study?
This clinical trial studies the following conditions: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8.
What interventions are being tested in trial NCT04660760?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Paclitaxel (DRUG), Ramucirumab (BIOLOGICAL), Trifluridine and Tipiracil Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04660760?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04660760 being conducted?
This trial has 15 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
RECRUITING · Phase 2
-
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
RECRUITING · Phase 2
-
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RECRUITING · Phase 2
-
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RECRUITING · Phase 2
-
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
All registered trials for this condition
Clinical Stage IV Gastric Cancer AJCC v8
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.